MHLW Suspends Mitsubishi Tanabe Operations For Fabricating Data
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's Ministry of Health, Labor and Welfare has suspended Mitsubishi Tanabe Pharma's manufacturing and sales operations for 25 days because it was determined a subsidiary of the company fabricated data for Medway Injection 5%, the world's first genetically engineered transgenic human serum albumin, MHLW officials said April 13, and regulatory authorities may level additional administrative penalties against the company
You may also be interested in...
Mitsubishi Tanabe's Key Products And M&A Rumors Tempered By Management Issues
TOKYO - Mitsubishi Tanabe has industry observers scratching their heads. On one hand, the company has rights in Asia for telaprevir, a high-profile hepatitis C treatment, and its oral multiple sclerosis therapy Gilenya (fingolimod) recently gained approval in the U.S. through ex-Japan licensee Novartis and is on file for approval in Japan. But the company's repeated supply chain irregularities raise concern over management's ability to handle its manufacturing quality control process
Mitsubishi Tanabe's Key Products And M&A Rumors Tempered By Management Issues
TOKYO - Mitsubishi Tanabe has industry observers scratching their heads. On one hand, the company has rights in Asia for telaprevir, a high-profile hepatitis C treatment, and its oral multiple sclerosis therapy Gilenya (fingolimod) recently gained approval in the U.S. through ex-Japan licensee Novartis and is on file for approval in Japan. But the company's repeated supply chain irregularities raise concern over management's ability to handle its manufacturing quality control process
Shionogi, Daiichi Sankyo, Mitsubishi Tanabe Await Subsidiary Action For Results: Japanese Earnings Roundup (Part 2 Of 2)
TOKYO - Offering a mixed bag of earnings results, Shionogi, Daiichi Sankyo, and Mitsubishi Tanabe all await action of some sort by subsidiaries to determine their FY2010 outcomes. For Shionogi, that means a need for a U.S. rebound from its Sciele subsdiary, Daiichi Sankyo is holding out for the results of Ranbaxy, and Mitsubishi Tanabe is eyeing the impact of its subsidiary-induced sales suspension. [Editor's note: Part 1 of the Japanese earnings roundup with Astellas and Eisai appeared yesterday (PharmAsia New, Aug. 3, 2010).]